New study tracks Real-World outcomes of combination therapy for advanced colon cancer
NCT ID NCT07494578
First seen Mar 31, 2026 · Last updated May 05, 2026 · Updated 3 times
Summary
This study is observing 300 patients with metastatic colorectal cancer who are being treated with a combination of two drugs: fluoropyrimidine (a chemotherapy) and bevacizumab (a targeted therapy). The goal is to see how long patients live and how long the cancer stays under control. The study is not testing a new treatment but rather collecting real-world data from 15 Italian centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00160, Italy
Conditions
Explore the condition pages connected to this study.